Overview
This study aims to investigate if the use of oral micronized natural progesterone is not inferior to the use of subcutaneous antagonist in preventing LH peak in controlled ovarian stimulation.
Description
The study will aim to include 150 women (egg donors): 75 per group and the principal variable will be the number of retrieved mature (MII) oocytes. Randomized, prospective, controlled, single center, phase IV study.
Eligibility
Inclusion Criteria:
- Eligibility for the oocyte donation program at Instituto Bernabeu.
- Age between 18 and 33 years
- BMI >18 and <30
- Overall antral follicle count >8
- Presence of both ovaries
- Ability to participate and comply with the study protocol
- Oral and written comprehension of Spanish
- Having given written consent
Exclusion Criteria:
- Endometriosis at any stage
- Any ovarian tumor whether benign or malignant
- Concurrent participation in another study
- Malabsorptive syndromes that may alter the efficacy of Seidigestan ® such as bariatric surgery, ulcerative colitis or Crohn's disease
- Irregular periods
- Hypogonadotropic hypogonadism
- Having received in the previous two months treatment with ovulation stimulators
- Having previously participated in the present study